Bayer said it needed to do more to boost sales of its drugs after lowering turnover estimates for its five most promising products to about € 3.75bn ( $ 4.26bn ) compared with an earlier € 6bn target for the top six drugs . The firm said it would enhance its pipeline of licensing and takeover deals to increase group earnings to € 16bn in revenue from € 12.2bn this year . The firm sold several businesses and said it would be hit by the ending of a heart drug patent and that this would affect sales of its eye ##wear .
Bayer said it needed to do more to boost sales of its drugs after lowering turnover estimates for its five most promising products to about €3.75bn ($4.26bn) compared with an earlier €6bn target for the top six drugs. The company said it would enhance its pipeline of licensing and takeover deals to increase group earnings to €16bn in 2022 from €12.2bn this year. The firm sold several businesses and said revenue would be hit by the ending of a heart drug patent and that competition would affect sales of its eye drug.